Mizuho Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $100
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh maintains a Buy rating on Intra-Cellular Therapies (NASDAQ:ITCI) and raises the price target from $96 to $100.
June 21, 2024 | 11:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho analyst Graig Suvannavejh maintains a Buy rating on Intra-Cellular Therapies and raises the price target from $96 to $100.
The Buy rating and increased price target from a reputable analyst at Mizuho is likely to boost investor confidence and positively impact ITCI's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100